AG10 for ATTR cardiomyopathy and ALXN2040 or PNH patients with extravascular haemolysis (EVH). “Alexion has established itself as a leader in complement biology, bringing life-changing benefits ...
which showed that crovalimab was as effective as Soliris at controlling the destruction of red blood cells (haemolysis) that characterises PNH, whilst also reducing the need for blood transfusions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback